2 contrasting FTSE income stocks investors should consider snapping up!

Income stocks paying dividends are an enticing prospect. Our writer breaks down two options for investors to take a closer look at.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Couple working from home while daughter watches video on smartphone with headphones on

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Financial services and pharmaceuticals are two very different industries. I think one stock from each of these could prove to be excellent income stocks.

The two picks I’m referring to are abrdn (LSE: ABDN) and GSK (LSE: GSK). Here’s why I reckon investors should consider buying some shares.

abrdn

Since the firm underwent its re-brand, the shares have struggled. However, this hasn’t been down to a name and branding change. Underlying issues haven’t helped the firm. However, I think it’s now on the right course to provide steady investor returns at an attractive level.

Before I dive into that side of things, it’s worth noting that abrdn shares are down 25% over a 12-month period. They were trading for 217p at this time last year, compared to 162p at current levels. It’s worth mentioning that macroeconomic volatility hasn’t helped either.

Recent strategic moves could help boost abrdn shares, as well as investor returns. For example, the business announced just last month it is cutting 500 jobs. Most of this will be management-related roles it feels it doesn’t need. In addition to this, it is outsourcing technology, which could help bring costs down and improve efficiency.

Furthermore, acquisitions such as interactive investor in 2022, and exposure to the growing US healthcare market via adding Tekla Capital Management to its offering could bear fruit. The former has already helped boost performance.

The natural risk for me is that of continued macroeconomic volatility hurting inflows and revenues, which underpin investor rewards. Rising interest rates and inflation have wreaked havoc on global economies. This has hurt most financial services stocks so this is a major risk I’ll continue to monitor.

However, a dividend yield of 9% and the shares looking attractively valued on a price-to-book ratio of 0.5 makes the stock one to seriously consider for returns and growth.

GSK

Since GSK split and formed Haleon for its consumer healthcare division, it now focuses solely on developing drugs and treatments, which is a potentially hugely lucrative market in its own right.

The shares are up 13% over a 12-month period. They were trading for 1,456p at this time last year, compared to current levels of 1,654p.

The allure of GSK stems from its long and storied track record in the drug development business. Plus, its good financial and performance track record. Many of its drugs are leaders in their respective fields. In addition to this, it is making real headway towards becoming a major player in the vaccines market. This is primarily linked to heavy investment in recent years.

For me, the biggest issue that could hinder GSK shares and payouts is that of continued investment and failure to create drugs and vaccines that make it to market. This could hurt its performance, balance sheet, and investor sentiment.

However, a dividend yield of 3.5% and the shares trading on a price-to-earnings ratio of 13 make it very attractive. I am conscious that dividends are never guaranteed. Ultimately, I reckon the shares could continue to climb. Furthermore, I’d expect the level of return to do so as well.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Sumayya Mansoor has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Closeup of "interest rates" text in a newspaper
Investing Articles

Here’s why 2025 could give investors a second chance at a once-in-a-decade passive income opportunity

Could inflation hold up interest rates in 2025 and give income investors a second opportunity to buy Unilever shares with…

Read more »

Investing Articles

As analysts cut price targets for Lloyds shares, should I be greedy when others are fearful?

As Citigroup and Goldman Sachs cut their price targets for Lloyds shares, Stephen Wright thinks the bank’s biggest long-term advantage…

Read more »

Investing Articles

Is passive income possible from just £5 a day? Here’s one way to try

We don't need to be rich to invest for passive income. Using the miracle of compounding, we can aim to…

Read more »

Middle-aged black male working at home desk
Investing Articles

If an investor put £20k into the FTSE All-Share a decade ago, here’s what they’d have today!

On average, the FTSE All-Share has delivered a mid-single-digit annual return since 2014. What does the future hold for this…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

One FTSE 100 stock I plan to buy hand over fist in 2025

With strong buy ratings and impressive growth, this FTSE 100 could soar in 2025. Here’s why Mark Hartley plans to…

Read more »

Investing For Beginners

If a savvy investor puts £700 a month into an ISA, here’s what they could have by 2030

With regular ISA contributions and a sound investment strategy, one can potentially build up a lot of money over the…

Read more »

artificial intelligence investing algorithms
Investing Articles

2 top FTSE investment trusts to consider for the artificial intelligence (AI) revolution

Thinking about getting more portfolio exposure to AI in 2025? Here's a pair of high-quality FTSE investment trusts to consider.

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Do I need to know how Palantir’s tech works to consider buying the shares?

Warren Buffett doesn’t know how an iPhone works. So why should investors need to understand how the AI behind Palantir…

Read more »